Psoriatic arthritis (moderate to severe) - adalimumab

Summary

Adalimumab should be offered as an option for treating adults with active and progressive psoriatic arthritis when:

• the person has arthritis with three or more tender joints and three or more swollen joints, and
• at least two other disease-modifying anti-rheumatic drugs (DMARDs), given on their own or together, haven’t worked.

Treatment with adalimumab should be started and supervised by a specialist physician who is experienced in diagnosing and treating psoriatic arthritis.

If the person’s psoriatic arthritis has not shown a measured response at 12 weeks, their treatment with adalimumab should be stopped.

Documents

For healthcare professionals

• TA125 Psoriatic arthritis (moderate to severe) - adalimumab: quick reference guide
• TA125 Psoriatic arthritis (moderate to severe) - adalimumab: guidance (MS Word format)
• TA125 Psoriatic arthritis (moderate to severe) - adalimumab: guidance

For patients, carers and the public

• TA125 Adalimumab ar gyfer trin arthritis soriatig: deall canllawiau NICE (fformat MS Word)
• TA125 Psoriatic arthritis (moderate to severe) - adalimumab: understanding NICE guidance (MS Word format)
• TA125 Psoriatic arthritis (moderate to severe) - adalimumab: understanding NICE guidance

Background information

• Review decision - March 2008
• 2007/044 NICE appraisal of rituximab and adalimumab for the treatment of arthritis
• TA125 Psoriatic arthritis (moderate to severe) - adalimumab: distribution list

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• TA125 Psoriatic arthritis (moderate to severe) - adalimumab: audit criteria
• TA125 Psoriatic arthritis (moderate to severe) - adalimumab: costing statement